Israel Biopharmaceutical Research and Development Market

In this report, the Israel biopharmaceutical R&D market is broadly segmented by products & services and end user. On the basis of products and services, the Israel biopharmaceutical R&D market is segmented into five broad categories, namely, instruments, consumables, bioreactors, services, and software. The instruments segment is further segmented into separation instruments, detection and screening instruments, imaging instruments, automation and high-throughput screening instruments, and others. Likewise, the consumables segment is divided into assays kits and reagents, cell culture media, cell lines, microplates, and others; while, the bioreactors segment is further classified into stainless steel bioreactors and single-use bioreactors.

The major factors driving the growth of this market are increasing number of pharmaceutical and biotechnology start-ups; government support; availability of sufficient venture capital (VC) funds; and availability of skilled, educated, and diverse workforce are driving the growth of the Israel biopharmaceutical R&D market. However, government regulations (such as drug pricing) are a major factor restraining the growth of this market. On the other hand, mergers and acquisitions between biopharmaceutical players and academia-industry partnerships are lucrative opportunities in this market.

The end users for the Israel biopharmaceutical R&D market are broadly classified into biotechnology/biopharmaceutical companies/CROs and academic and research institutes. The biotechnology/biopharmaceutical companies/CROs segment dominated the market with a share of 70.4% in 2014. Biopharmaceutical companies are increasingly investing in R&D activities in order to launch novel drugs.

Top market players that have established their base in the Israel bio-pharma research market are Thermo Fisher Scientific Inc. (U.S.), Merck KGAA (Germany), Perkinelmer Inc. (U.S.), Bio-Rad Laboratories Inc. (U.S.), Becton, Dickinson and Company (U.S.).

Thermo Fisher Scientific Inc. entered in the Israel biopharmaceutical R&D market with the acquisition of Life Technologies Israel Ltd. Life Technologies had well established network in Israel, thus, after acquisition, it broaden Thermo Fisher’s product portfolio. In 2014, the company accounted for the largest share of ~xx% in the Israel biopharmaceutical R&D market in 2014. The large share of the company attributed to its extensive equipment and reagent portfolio. The company’s broad clinical portfolio which includes drug discovery & development, clinical & translational research services is specifically designed to cater needs of biopharmaceutical R&D.

Merck KGaA accounted for the second-largest share of ~xx% in the Israel biopharmaceutical R&D market. It is engaged in providing top notch analytical solutions, chromatography instruments and reagents and life sciences research tools. The company has maintained its footprint in the market through its strong distribution network and catering needs of life sciences R&D department efficiently.

Bio-Rad laboratories, Inc. held the third position in the market, with a share of ~xx% in 2014. The company has broad portfolio and strong network of distributors in Israel. Bio-Rad Haifa, Ltd. (Israel), innovative research and development centre of Bio-Rad Laboratories Inc. is engaged in development of analytical tools and instrumentation for life science research and also plays role as its exclusive distributor.

PerkinElmer and Becton, Dickinson and Company (BD) contributed ~xx% and ~xx% of Israel biopharmaceutical R&D market owing to their instruments and reagent portfolio for biopharmaceutical R&D